Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Roche has agreed to acquire Dutalys, an Austrian biotech firm specializing in fully human bispecific antibodies, for $133.75 million, plus payments of up to $355 million if certain milestones are hit. Bispecific antibodies contain fragments of two monoclonal antibodies, allowing them to bind to two different antigens. Roche says Dutalys’s technology enables development of products that can treat diseases not addressable by conventional bispecific antibodies.
This article has been sent to the following recipient: